Prelude Therapeutics Incorporated
PRLD · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $6,500 | $0 | $0 | $4,000 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $425 | $0 | $0 | $0 |
| Gross Profit | $6,075 | $0 | $0 | $4,000 |
| % Margin | 93.5% | – | – | 100% |
| R&D Expenses | $21,708 | $25,784 | $28,816 | $31,620 |
| G&A Expenses | $0 | $6,410 | $5,790 | $6,211 |
| SG&A Expenses | $4,785 | $6,410 | $5,790 | $6,211 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $26,493 | $32,194 | $34,606 | $37,831 |
| Operating Income | -$20,418 | -$32,194 | -$34,606 | -$33,831 |
| % Margin | -314.1% | – | – | -845.8% |
| Other Income/Exp. Net | $693 | $963 | $2,521 | $5,100 |
| Pre-Tax Income | -$19,725 | -$31,231 | -$32,085 | -$28,731 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$19,725 | -$31,231 | -$32,085 | -$28,731 |
| % Margin | -303.5% | – | – | -718.3% |
| EPS | -0.26 | -0.41 | -0.42 | -0.38 |
| % Growth | 36.6% | 2.4% | -10.5% | – |
| EPS Diluted | -0.26 | -0.41 | -0.42 | -0.38 |
| Weighted Avg Shares Out | 76,132 | 75,994 | 75,986 | 75,896 |
| Weighted Avg Shares Out Dil | 76,132 | 75,994 | 75,986 | 75,896 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $425 | $433 | $435 | $489 |
| EBITDA | -$19,300 | -$31,761 | -$34,171 | -$33,342 |
| % Margin | -296.9% | – | – | -833.6% |